Navigation Links
New Data on Patient-Reported Improvements in Quality of Life Measures and Other Clinical Responses in Moderate to Severe Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol) Highlighted at American College of Rheumatology Meeting
Date:11/7/2011

ertolizumab Pegol Plus Methotrexate in Japanese Rheumatoid Arthritis Patients with An Inadequate Response to Methotrexate
  • 1218 - Monday, November 7, 9:00 am - 6:00 pm, Poster Hall

  • Efficacy and Safety of Certolizumab Pegol without Methotrexate Co-Administration in Japanese Patients with Active Rheumatoid Arthritis
    • 1220 - Monday, November 7, 9:00 am - 6:00 pm, Poster Hall

About Rheumatoid Arthritis

RA affects more than 1.3 million Americans, and it is estimated that 5 million people suffer from RA globally. Prevalence is not split evenly between genders, since women are three times more likely to be affected than men. Although RA can affect people of all ages, the onset of the disease usually occurs between 35-55 years of age.

About Cimzia

Certolizumab pegol is the only PEGylated anti-TNF (Tumor Necrosis Factor).  It has a high affinity for human TNF-alpha, selectively neutralizing the pathophysiological effects of TNF-alpha.  Over the past decade, TNF-alpha has emerged as a major target of basic research and clinical investigation.  This cytokine plays a key role in mediating pathological inflammation, and excess TNF-alpha production has been directly implicated in a wide variety of diseases.  The U.S. Food and Drug Administration (FDA) has approved certolizumab pegol for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderate to severe active disease who have had an inadequate response to conventional therapy.  It is also approved for the treatment of adults with moderately to severely active rheumatoid arthritis.  Certolizumab pegol was approved in Switzerland for induction of a clinical response and for the maintenance of a clinical response and remission in p
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Amylin to Present Data Showing Investigational Metreleptin Treatment Led to Long-Term Improvements in Diabetes and Lipid Control in Patients with Lipodystrophy
2. QNEXA® Phase 3 Data in The Lancet Show Significant Weight Loss and Broad Improvements in Co-Morbidities
3. NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development
4. Reportlinker Adds Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
5. Terumo Cardiovascular Systems Reaches Agreement on Terms of Consent Decree With FDA Regarding Quality System Improvements
6. Photocure Announces Positive Allumera™ Trial Results for Delivering Significant Skin Appearance Improvements
7. Improvements in Recurrence-Free Survival in Early Stages of Colorectal Cancer Will Limit Growth of Drug Treatment Opportunities for Advanced Disease
8. Neupro® (Rotigotine) Provided Clinically Relevant Improvements in Health-Related Quality of Life for People with Parkinsons Disease
9. Ekahau RTLS Enables Improvements in Staff Safety in Austrian Psychiatric Hospital
10. Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV(R) (Velaglucerase Alfa) Through 69 Months
11. Phase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabetic Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 ... announced the addition of the "Investigation Report ... their offering. Developed by AstraZeneca plc, ... an important drug for the treatment of schizophrenia. ... quetiapine was listed in the Catalogue of Drugs ...
(Date:8/28/2015)... , Aug. 28, 2015 ... announced the addition of the "Investigation Report ... their offering. Developed by Pharmacia & ... receptor agonist which effectively reduces intraocular pressure. As ... latanoprost (under the trade name of Xalatan) entered ...
(Date:8/28/2015)... , August 28, 2015 The scientific ... collaboration with one of the leading academics in the field ... world record holder in life extension for model animals - ... biology of aging and age-related diseases, primarily, around the stability ... has just been published as "Stability analysis of a model ...
Breaking Medicine Technology:China Quetiapine Market Investigation Report 2010-2019 2China Latanoprost Market Investigation Report 2015-2019 2Gero: Physics Meets Biology to Help Defeat Aging 2Gero: Physics Meets Biology to Help Defeat Aging 3
... PARIS and NEW DELHI, India, Sept. 20 ... subsidiary of Cellectis (Alternext: ALCLS), and Helix BioService ... that they will join forces for the promotion ... India. Helix Biocon is a young company comprised ...
... A unit of the Government of Ukraine today ... a U.S. company that is alleged to be part ... vaccines and other pharmaceuticals.  The case was brought by ... procurement and storage of medicines and medical supplies for ...
Cached Medicine Technology:Cellectis bioresearch and Helix Biocon Join Forces for the Promotion of cGPS® and cGPS® Custom Kits and Cell Line Engineering Services in India 2Cellectis bioresearch and Helix Biocon Join Forces for the Promotion of cGPS® and cGPS® Custom Kits and Cell Line Engineering Services in India 3Ukrainian Government Unit Sues in U.S. - Alleges Corrupt Scheme in Vaccine Purchases 2
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... abuse, or those who might personally be struggling with chemical dependency, may be ... from Best Drug Rehabilitation, a results-driven holistic treatment center for addiction located in ...
(Date:8/28/2015)... ... 28, 2015 , ... Drugs and alcohol abuse by employees ... new approach on solutions in his new book ":Unraveling The Psychological Mystery of ... together for meaningful group meetings. "This would educate the employees on not ...
(Date:8/28/2015)... ... August 28, 2015 , ... Dr. Gregory K. Toumayan, D.C., Q.M.E., is now ... shoulder pain, hip pain, neck pain, stiffness, muscle spasms, and numbness. ... of Illinois, and then went on to earn his title of Doctor of Chiropractic ...
(Date:8/28/2015)... ... August 28, 2015 , ... Mendon, IL, home of the Adams County Fairgrounds, ... all for a good cause. In its second year, the “Music With A Mission” ... Drug Rehabilitation. The “Mission” of “Music With A Mission” is to raise money to ...
(Date:8/28/2015)... ... 28, 2015 , ... The newest therapy to receive orphan drug status for ... time soon, according to educational website Surviving Mesothelioma. Click here to read their ... for mesothelioma last week from the FDA, will now head into Phase I clinical ...
Breaking Medicine News(10 mins):Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 3Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 3Health News:Best Drug Rehabilitation Sponsors "Music With A Mission" Concert Featuring Avenue Beat 2Health News:Surviving Mesothelioma Puts New Orphan Drug into Perspective in New Article 2
... Dec. 1 MassMutual Retirement Services Division has added ... Nonprofit activity has more than tripled in 2008 compared ... Dan Darby joined MassMutual on December 1 ... reports to M. Palmer Whitney, national managing director, nonprofit ...
... 1 The Food Allergy & Anaphylaxis Network (FAAN) ... CEO, replacing Founder Anne Munoz-Furlong, who is retiring. , ... to FAAN extensive knowledge of anaphylaxis, a severe, potentially ... Senior Director of Marketing, she led the marketing team ...
... supplements can also trigger acute organ failure, study says ... the single largest class of drugs that cause idiosyncratic ... accounts for about 13 percent of cases of acute ... most common cause of death from acute liver failure. ...
... Dry-needling, steroids effective against plantar fasciitis, researchers say ... researchers say they,ve developed a fast, effective, non-invasive ... plantar fasciitis. , Using a combination of "dry-needling" ... say their approach achieved a 95 percent success ...
... as one in five of all Americans who survive a ... emotionally paralyzed survivors of 9/11 and broken up survivors, families. ... lower the chance of developing the disorder, but thanks to ... PTSD may be just around the corner. , Prof. Joseph ...
... will die of AIDS. In fact, nearly 7,000 people die each day ... 1 is World AIDS Day, a day of awareness and outreach to help ... Day 2008 is You Can Make a Difference and ... as well as helping dispel the myths and misconceptions about HIV. , ...
Cached Medicine News:Health News:MassMutual Retirement Services Adds Two to Nonprofit Sales Team 2Health News:MassMutual Retirement Services Adds Two to Nonprofit Sales Team 3Health News:FAAN Names New CEO 2Health News:Antibiotics Largest Cause of Drug-Induced Liver Damage 2Health News:New Twist on Treatment of Foot Pain 2Health News:New Twist on Treatment of Foot Pain 3Health News:Easing the stress of trauma 2Health News:In Support of World AIDS Day, FHSSA Announces New Partnerships That Include the First In-Country Partnerships in Namibia and The Gambia 2
For the qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma and whole blood specimens...
... HumaPen MEMOIR is the first and only insulin pen ... and amount of your last 16 doses (including priming ... insulin you last took. With HumaPen MEMOIR, you simply ... one-unit increments (up to 60 units) after initial set-up. ...
Assay development using client's antibodies and antigens to meet diagnostic target...
Colloidal Gold Conjugated, Streptavidin - 50 OD...
Medicine Products: